Abbott Laboratories vs. Johnson & Johnson
Abbott Laboratories (ABT) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| ABT | JNJ | |
|---|---|---|
| Market Cap | $185.36 billion | $613.10 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | — | $21.04 billion |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| ABT | JNJ | |
|---|---|---|
| P/E Ratio | — | 29.57 |
| Price / Book | — | 7.22 |
| Price / Sales | — | 6.26 |
ABT and JNJ split the valuation factors evenly.
Profitability
| ABT | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | — | 24.76% |
ABT and JNJ split the profitability factors evenly.
Dividend
| ABT | JNJ | |
|---|---|---|
| Dividend Yield | 2.39% | 2.10% |
| Payout Ratio | — | 62.18 |
ABT leads on 1 of 1 dividend factors.
Risk & Sentiment
| ABT | JNJ | |
|---|---|---|
| Short Interest | 0.57% | 0.67% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.